Opus Genetics Q2 net loss $8.1M; LCA5 trial enrollment completed

Opus Genetics, Inc.

Net loss of $8.1M ($0.08 basic EPS) vs $7.4M loss in Q2 2025; revenue fell to $0.8M from $2.9M.
Cash and equivalents $88.8M; runway into 2029, excluding potential warrant proceeds or milestones.
OPGx-BEST1 Cohort 1 topline data expected second week of September 2026.
OPGx-LCA5 registrational trial enrollment completed; dosing expected Q4 2026 with topline data by end of 2027.
OPGx-RDH12 enters clinic Q4 2026; OPGx-MERTK clinical testing Q1 2027; OPGx-RHO clinical testing H2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.